Citius Oncology, Inc. (CTOR)
0.7003
+0.03
(+4.37%)
USD |
NASDAQ |
Oct 21, 16:00
Citius Oncology EPS Diluted (Quarterly) : -0.0827 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0827 |
| March 31, 2026 | -0.266 |
| December 31, 2025 | -0.0633 |
| September 30, 2025 | -0.0617 |
| June 30, 2025 | -0.075 |
| March 31, 2025 | -0.1081 |
| December 31, 2024 | -0.0931 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.0379 |
| March 31, 2024 | 0.0736 |
| December 31, 2023 | 0.1156 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0177 |
| June 30, 2023 | 0.0684 |
| March 31, 2023 | 0.0679 |
| December 31, 2022 | 0.0422 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| January 31, 2022 | 0.00 |
| October 31, 2021 | 0.00 |
| July 31, 2021 | 0.00 |
| April 30, 2021 | -0.0014 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Citius Pharmaceuticals, Inc. | -0.3387 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.924M |
| Revenue (Quarterly) | 1.494M |
| Total Expenses (Quarterly) | 10.42M |
| Enterprise Value | 67.71M |
| Gross Profit Margin (Quarterly) | -48.09% |
| Profit Margin (Quarterly) | -597.4% |
| Earnings Yield | -67.64% |
| Normalized Earnings Yield | -67.64 |